Trump Administration Ends Medicare Part D Premium Stabilization Program

The Trump administration has announced it will discontinue the Medicare Part D Premium Stabilization Demonstration after 2026, ending a temporary subsidy program that was introduced to address premium volatility following changes mandated by the Inflation Reduction Act (IRA).

This decision has brought renewed attention to the ongoing debate over the cost, sustainability, and future direction of Medicare Part D. While some critics warn that ending the program could lead to higher premiums for beneficiaries, officials argue that the market is now stable enough to function without additional federal support.

The Centers for Medicare and Medicaid Services (CMS) made the announcement on July 28, stating that the demonstration, which began in 2025, will conclude at the end of 2026. According to CMS, Part D plan sponsors now have sufficient experience with the redesigned benefit to accurately develop bids for 2027. The agency emphasized that the program was initially implemented to address volatility and variation in standalone premiums after the IRA restructured the Part D benefit and capped out-of-pocket spending for beneficiaries. CMS announcement

Details of the Subsidy Program

The Premium Stabilization Demonstration was launched by the Biden administration for the 2025 plan year. It was designed as a voluntary measure to support insurers and minimize premium spikes following the significant changes introduced by the IRA. According to CMS, the demonstration aimed to provide stability for people with Medicare during the transition to the new benefit structure. CMS 2025 fact sheet

The IRA made several key changes to Medicare Part D. Starting in 2025, it capped annual out-of-pocket spending for beneficiaries at $2,000 and eliminated the coverage gap phase, often referred to as the "donut hole." These changes were projected to save enrollees an average of 30% in annual out-of-pocket prescription drug costs. However, the restructuring also shifted more costs onto the federal government and insurers.

CMS data shows that the national average monthly bid amount for 2027 will be $296.05, with the base beneficiary premium set at $41.33. The IRA also includes a provision that limits annual premium increases to no more than 6% through 2029, providing a statutory safeguard against sudden premium hikes.

Arguments Over Cost and Value

Supporters of ending the demonstration, including policy analyst Chris Jacobs, have argued that the temporary bailout was an "extralegal" measure that shifted billions in costs to taxpayers. Jacobs has pointed out that seniors' share of Part D costs via premiums has fallen to about 13%, with taxpayers now covering roughly 87% of program spending. He cited a recent Medicare trustees report estimating that the long-term cost of Part D has increased by about one-third, or $5 trillion, compared to the previous year's report.

"By ending the Biden administration’s unilateral insurer bailout, the Trump administration served as a smart steward of scarce taxpayer dollars, while restoring more of a competitive balance to Part D."

— Chris Jacobs, Juniper Research Group CEO

CMS, in its announcement, stated that with two years of experience under the new benefit design, insurers can now price their products with greater certainty. This, the agency said, reduces the need for additional federal intervention. CMS also noted that the statutory premium stabilization provision from the IRA remains in effect through 2029, continuing to cap annual premium increases and offering ongoing protection for beneficiaries against large premium jumps.

Reactions and What to Expect

The decision has drawn mixed reactions from various stakeholders. The California Democratic Party criticized the move, claiming on X that "25 million people, mainly seniors, count on Medicare Part D to afford their prescriptions. Donald Trump is putting their health on the line by ending the program." However, both Jacobs and CMS clarified that the underlying Part D program is not ending—only the temporary demonstration is concluding.

CMS has projected that most enrollees will see either no change or a decline in premiums (25%), or an increase of under $10 per month (30%) as a result of the change. The agency plans to release final average Medicare Advantage and Part D premiums, along with other key information, in September when the 2027 plan landscape is finalized.

The debate over the future of Medicare Part D continues as policymakers weigh the tradeoffs between premium stability, taxpayer costs, and long-term program solvency. While the demonstration was intended as a short-term measure to ease the transition to the new benefit structure, its conclusion signals a return to normal market operations for insurers and beneficiaries alike. The ongoing statutory protections from the IRA, including the cap on annual premium increases, are expected to provide continued stability for enrollees in the coming years.

As the Medicare Part D landscape evolves, stakeholders will be watching closely to see how premiums, federal spending, and beneficiary protections interact under the new framework. The outcome may influence future policy decisions regarding the balance between government intervention and market forces in the Medicare prescription drug program.